Monopar, National University of Singapore Team Up For Preclinical Assessment Of MNPR-202 In Cancer Settings

by Vandana Singh, Benzinga Editor

June 3, 2021 12:24 PM | 1 min read | Make a Comment

Monopar Therapeutics Inc MNPR collaborates with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in multiple types of cancer.
MNPR-202 was designed to retain the same potentially non-cardiotoxic backbone as camsirubicin but is modified, which may enable it to work in certain cancers that are resistant to camsirubicin and doxorubicin (chemo).
The company expects camsirubicin to enter a dose-escalation run-in clinical trial in advanced soft tissue sarcoma in the second half of 2021.
CSI Singapore will explore how the immune system recognizes cancer cells treated with MNPR-202 and related analogs.
Price Action: MNPR shares are down 0.65% at $6.09 during the market session on the last check Thursday.

Posted In: Biotech News Health Care Contracts FDA General Briefs cancer

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.